These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Comparison of bioavailability between nimotop and nimodipine tablet].
    Author: Shi XJ, Wang HT, Wei Y, Zhang JH, Zhang LL, Zhong MK.
    Journal: Yao Xue Xue Bao; 1997 Sep; 32(9):708-10. PubMed ID: 11596299.
    Abstract:
    A new analytical method was established for determining plasma level of nimodipine using HPLC and its application to determine the bioavailability of nimodipine. Experiments were performed on a Waters Model Baseline 810 System instrument. A 3.9 mm x 200 mm stainless steel column was packed with YWG-C18(10 microns) as the stationary phase. The mobile phase was a mixture solution of methanol--water (60/40, v/v) with 1.00 ml.min-1 at 35 degrees C. The detector was set at 358 nm. The plasma samples were extracted with ether--n-hexane (1:1). Calibration curve was linear (gamma = 0.9999) in the concentration range of 5-300 ng.ml-1. The within-day and between-day precision (RSD) were less than 3% and 5%, respectively, with average recoveries of 97.67%-102.3%. The study on bioavailability of numodipine between tablet A (made in China) and nimotop (Bayer, Germany) was carried out in 8 volunteers at the oral dose of 120 mg by cross-over method. Two-compartment open model was suitable for describing the disposition of nimodipine. The main pharmacokinetic parameters were shown in Tab 1 and mean plasma concentration--time curve of nimodipine was shown in Fig 1. The results indicate that tablet A exhibited a lower bioavailability (relative to nimotop). We suggest that the product tablet A must be improved in formula and technology.
    [Abstract] [Full Text] [Related] [New Search]